Evidence map›Paper›PMID 40489109›Full record

ArticleJAMA network open2025

Long-Term Coronary Microvascular and Cardiac Dysfunction After Severe COVID-19 Hospitalization.

Rebecka Steffen Johansson, Daniel Loewenstein, Klara Lodin, Judith Bruchfeld, Michael Runold, Marcus Ståhlberg, Hui Xue, Peter Kellman, Kenneth Caidahl, Henrik Engblom and 1 more

Erratum issuedAbstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Microvascular Dysfunction and Redox Imbalance in Long COVID.Microcirculation (New York, N.Y. : 1994) · 2026
    Article
  2. Review
  3. Community-acquired pneumonia withJournal of thoracic disease · 2026
    Article
  4. Errors in Results.JAMA network open · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Rebecka Steffen JohanssonDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Daniel LoewensteinDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Klara LodinDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Judith BruchfeldDivision of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Michael RunoldDepartment of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
Marcus StåhlbergDepartment of Medicine, Solna, Karolinska Institutet, Solna, Sweden.
Hui XueHealth Futures, Microsoft Research, Redmond, Washington.
Peter KellmanNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Kenneth CaidahlDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.
Henrik EngblomDepartment of Clinical Sciences Lund, Clinical Physiology, Skåne University Hospital, Lund University, Lund, Sweden.
Jannike NickanderDepartment of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: COVID-19 can lead to long-term cardiopulmonary symptoms and is associated with coronary microvascular dysfunction (CMD). However, long-term data on CMD after severe COVID-19 are lacking. Objective: To investigate long-term left ventricular function and the presence of CMD after severe COVID-19. Design, Setting, and Participants: This case-control study was conducted among patients at a single center from the prospective Follow-Up of Patients With Severe COVID-19 (UppCov) study, with follow-up multiparametric perfusion cardiovascular magnetic resonance (CMR) at 10 months after discharge from November 2020 to February 2021. Patients previously hospitalized due to severe COVID-19 (ventilatory support, oxygen flow ≥5 L/min, or both) with or without cardiac involvement (troponin t > 14 ng/L, pulmonary artery pressure >34 mm Hg, or both) were compared with historical sex- and age-matched volunteers without symptomatic ischemic heart disease. Standard contraindications to adenosine CMR were applied. Data were analyzed between March 2023 and March 2025. Exposure: Hospitalization due to severe COVID-19. Main Measures and Outcomes: Comprehensive CMR included native T1, native T2, extracellular volume, adenosine stress and rest perfusion mapping, gadolinium enhancement, and cine imaging. Comorbidities, medications, symptoms at follow-up, and details regarding hospitalization were obtained from patient records. Results: The study included 37 patients with COVID-19 (mean age, 56 years [95% CI, 53 to 61 years]; 28 male [75.7%]) and 22 healthy volunteers (mean age, 51 years [95% CI, 45 to 57 years]; 12 male [54.4%]). Patients with COVID-19 compared with healthy patients demonstrated reduced mean stress perfusion (2.80 mL/min/g [95% CI, 2.53 to 3.07 mL/min/g] vs 3.43 mL/min/g [95% CI, 3.13 to 3.74 mL/min/g]; P = .003), impaired mean global longitudinal strain (-17% [95% CI, -18% to -16%] vs -19% [-20% to -18%]; P = .003), and impaired mean global circumferential strain (-16% [95% CI, -17% to -15%] vs -19% [-20% to -18%]; P = .001). There were no differences in stress perfusion or myocardial perfusion reserve in the COVID-19 group between patients with vs without cardiovascular risk factors or cardiac symptoms. Conclusions and Relevance: In this study, patients with COVID-19 exhibited long-term reduced stress perfusion indicating CMD, along with declined left ventricular function by global longitudinal strain and global circumferential strain. Lack of variation in stress perfusion between patients with and without cardiovascular risk factors may suggest CMD due to severe COVID-19, warranting further investigation to elucidate mechanisms and guide potential therapies.

Indexed as

COVID-19Ventricular Dysfunction, LeftAgedCase-Control StudiesCoronary CirculationFemaleHospitalizationHumansMaleMicrocirculationMiddle AgedProspective StudiesSARS-CoV-2

Identifiers

PMID40489109
PMCPMC12150193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.